5 results
8-K
EX-99.2
SCNX
Scienture Holdings, Inc.
24 Sep 24
Amendments to Articles of Incorporation or Bylaws
4:05pm
and cater to different market segments. Scienture is a fully fitted company with strategic capabilities across R&D, Manufacturing, Sales and Marketing
DEF 14C
SCNX
Scienture Holdings, Inc.
28 Aug 24
Information statement
4:05pm
and Development Expense (“R&D”)
R&D expenses were $1.5 million and $1.0 million for the six months ended June 30, 2024 and 2023, respectively … with R&D and is reported separately from R&D due to materiality.
General and Administrative Expense (“G&A”)
G&A expenses were $1.4 million and $0.3
PRE 14C
SCNX
Scienture Holdings, Inc.
15 Aug 24
Preliminary information
9:57pm
of costs related to the products in the U.S. in prior periods.
Research and Development Expense (“R&D”)
R&D expenses were $1.5 million and $1.0 million … entry into the Kesin Termination Agreement. This activity is associated with R&D and is reported separately from R&D due to materiality.
General
8-K
EX-99.1
SCNX
Scienture Holdings, Inc.
31 Jul 24
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million
5:25pm
areas, indications and cater to different market segments. Scienture’s is a fully fitted company with strategic capabilities across R&D, Manufacturing
8-K
SCNX
Scienture Holdings, Inc.
31 Jul 24
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million
5:25pm
margins. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in new molecule discovery and product development
- Prev
- 1
- Next